Study Examines Adverse Events Associated With Human Papillomavirus Vaccine

An analysis of the adverse events reported following distribution of quadrivalent human papillomavirus recombinant vaccine since 2006 indicates that adverse event rates were consistent with pre-licensing data and expected background rates of other vaccines, with the exception of a higher proportion of reports of fainting and blood clots, according to a new study.

Read the whole article on Science Daily

More from Science Daily